Mary Wilson
Well-known member
Published: 18 May 2023
https://doi.org/10.1093/infdis/jiad134
Xin Xia, Zhong-Ming Tan, Peng Wan, Hao Zheng, Rong Tang, Xiao-Qin Chen, Xi-Ling Guo, Tao Zhu, Jia-Lu Feng, Jin Zhong ... Show more
Abstract
Background
An orally aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) has recently been authorized for boosting immunization in China. Our study aims to assess the environmental impact of the use of aerosolised Ad5-nCoV.
Methods
We collected air samples from rooms, swabs from the setting desks of the vaccine nebuliser, mask samples from participants and blood samples of nurses who administered the inoculation in the clinical trials. The viral load of adenovirus type-5 vector in the samples and the antibody levels against the wild-type SARS-CoV-2 strain in serum were detected.
Results
Only one (4.00%) air samples collected before the initiation of vaccination was positive, which were almost positive during and after the vaccination (97.96%, 100%, respectively). All nurses in the trial A showed at least four-fold increase of the neutralizing antibody against the SARS-CoV-2 after the initiation of the study. In trial B, the positive proportion of the mask samples was 72.97% at 30 minutes after vaccination, 8.11% at day 1, and 0% at days 3, 5, and 7, respectively.
Conclusion
The vaccination with the orally aerosolised Ad5-nCoV could have some spillage of the vaccine vector viral particles in the environment and cause human exposure.
https://watermark.silverchair.com/j...6GubZfDQfA1p8ac4-Xlow72RwwofVniTadmanB38SyzpQ
https://doi.org/10.1093/infdis/jiad134
Xin Xia, Zhong-Ming Tan, Peng Wan, Hao Zheng, Rong Tang, Xiao-Qin Chen, Xi-Ling Guo, Tao Zhu, Jia-Lu Feng, Jin Zhong ... Show more
Abstract
Background
An orally aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) has recently been authorized for boosting immunization in China. Our study aims to assess the environmental impact of the use of aerosolised Ad5-nCoV.
Methods
We collected air samples from rooms, swabs from the setting desks of the vaccine nebuliser, mask samples from participants and blood samples of nurses who administered the inoculation in the clinical trials. The viral load of adenovirus type-5 vector in the samples and the antibody levels against the wild-type SARS-CoV-2 strain in serum were detected.
Results
Only one (4.00%) air samples collected before the initiation of vaccination was positive, which were almost positive during and after the vaccination (97.96%, 100%, respectively). All nurses in the trial A showed at least four-fold increase of the neutralizing antibody against the SARS-CoV-2 after the initiation of the study. In trial B, the positive proportion of the mask samples was 72.97% at 30 minutes after vaccination, 8.11% at day 1, and 0% at days 3, 5, and 7, respectively.
Conclusion
The vaccination with the orally aerosolised Ad5-nCoV could have some spillage of the vaccine vector viral particles in the environment and cause human exposure.
https://watermark.silverchair.com/j...6GubZfDQfA1p8ac4-Xlow72RwwofVniTadmanB38SyzpQ